Our findings suggest that all-cause mortality was higher in certain subgroups of ANA-positive participants with a history of cancer (i.e., men and older enrollees), but sample sizes were too small to assess associations between ANA and cancer mortality in these subgroups. The gene discussed is BTG3; the disease is cancer.